Adage Capital Partners Gp, L.L.C. Fibrogen Inc Transaction History

Adage Capital Partners Gp, L.L.C.

$54.6 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$15.95 - $25.18 $28.7 Million - $45.3 Million	-1,800,000 Reduced 67.92%	850,000 $15.9 Million
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $1.33 Million - $1.77 Million	-100,000 Reduced 3.64%	2,650,000 $42.5 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $31.4 Million - $40.2 Million	2,750,000 New	2,750,000 $35.8 Million
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $2.02 Million - $2.28 Million	-50,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$23.3 - $45.96 $1.17 Million - $2.3 Million	50,000 New	50,000 $1.74 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $51.9 Million - $72.1 Million	-1,500,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $7.4 Million - $9.69 Million	-200,000 Reduced 11.76%	1,500,000 $55.5 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $22.8 Million - $36.1 Million	650,000 Added 61.9%	1,700,000 $76.8 Million
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $2.14 Million - $3 Million	-50,000 Reduced 4.55%	1,050,000 $57.1 Million
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $23 Million - $36.5 Million	607,000 Added 123.12%	1,100,000 $50.9 Million
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $5.63 Million - $6.73 Million	-100,000 Reduced 16.86%	493,000 $30 Million
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $9.29 Million - $13.4 Million	-207,000 Reduced 25.87%	593,000 $37.1 Million
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $16.5 Million - $22.5 Million	-364,900 Reduced 31.32%	800,000 $37 Million
Q4 2017 Feb 14, 2018	BUY	$41.95 - $60.1 $3.15 Million - $4.51 Million	75,000 Added 6.88%	1,164,900 $55.2 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $36.4 Million - $58.7 Million	1,089,900	1,089,900 $58.6 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account